CBX4 and colorectal carcinoma: Further investigations are warranted to dissect the molecular mechanisms underlying CBX4-mediated oncogenic activity in CRC and to determine whether its inhibition could be leveraged therapeutically, either alone or in combination with existing treatment strategies.